Evidence map›Paper›PMID 39695472›Full record

ArticleBMC public health2024

A retrospective chart review and thematic analysis of patients seeking mpox vaccination during the initial outbreak in 2022-2023: evaluation of access, motivations, and stigma.

Kody Muncaster, Chelsea Masterman, Tamara Barnett, Robert A Kozak, Erin Mandel, Karen Campbell, Mia J Biondi Mj

Abstract read
In one paragraph

Article in BMC public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kody MuncasterSchool of Nursing, Health, York University, Rm. 329A, Health, Nursing and Environmental Studies Building, 104 Scholars Walk, Toronto, M3J 1P3, Canada.
Chelsea MastermanSchool of Nursing, Health, York University, Rm. 329A, Health, Nursing and Environmental Studies Building, 104 Scholars Walk, Toronto, M3J 1P3, Canada.
Tamara BarnettSchool of Nursing, Health, York University, Rm. 329A, Health, Nursing and Environmental Studies Building, 104 Scholars Walk, Toronto, M3J 1P3, Canada.
Robert A KozakSunnybrook Health Sciences Centre, Toronto, Canada.
Erin MandelSchool of Nursing, Health, York University, Rm. 329A, Health, Nursing and Environmental Studies Building, 104 Scholars Walk, Toronto, M3J 1P3, Canada.
Karen CampbellSchool of Nursing, Health, York University, Rm. 329A, Health, Nursing and Environmental Studies Building, 104 Scholars Walk, Toronto, M3J 1P3, Canada.
Mia J Biondi MjSchool of Nursing, Health, York University, Rm. 329A, Health, Nursing and Environmental Studies Building, 104 Scholars Walk, Toronto, M3J 1P3, Canada. mbiondi@yorku.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMpox was identified in many previously non-endemic countries, including Canada, as of May 2022. In response to the increase in cases in Canada, and more specifically the province of Ontario, the vaccine Imvamune was rolled out. Eligibility was governed by provincial health authorities, and the response varied by region. In addition, because eligibility language was describing certain types of sexual activity, there was potential for harm. The aim of this study was to further explore the experiences of vaccine recipients as it pertained to obtaining the vaccine, access to information and vaccination, self-assessment of risk, perspectives on vaccine rollout, stigma, and community support.

methodsAs a part of care, a clinic in downtown Toronto, Ontario, began hosting mpox immunizations clinics between July of 2022 and March of 2023 with a standard set of clinical intake questions. Following this period, we conducted a retrospective chart review of 113 Imvamune vaccine recipients. Both descriptive quantitative data and thematic qualitative analysis was completed.

resultsOne hundred thirteen patients received one or two doses of Imvamune between July 2022 and March 2023. The average age was 49 (range 17-78). Patients were not asked sex or gender; however, 111 patients had a male sex listed on their health card and three female sex, one of whom self-identified as a transwoman, with the remainder not having had their sex inputted into their medical records. Through descriptive thematic analysis, this study found the following recurrent themes mentioned by patients in the data set: 1) eligibility, 2) rollout and access, 3) mis/information in the media, 4) stigma.

conclusionsThere is little Canadian data on mpox vaccine rollout beyond epidemiologic and cohort information. Understanding the difficulties and stigma that were faced by vaccine recipients is crucial to ensure that when a public health initiative is initiated, that past traumas are not replicated. This study provides valuable patient perspectives in how to improve ongoing rollout, as well as how a campaign that includes a sexual health component may be more sensitively considered in the future.

Indexed as

Mpox, MonkeypoxSocial StigmaVaccinationAdolescentAdultAgedDisease OutbreaksFemaleHealth Services AccessibilityHumansMaleMiddle AgedMotivationOntarioPatient Acceptance of Health CareRetrospective StudiesEquityMpoxPreventionRisksStigmaVaccination

Identifiers

PMID39695472
PMCPMC11653796

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.